Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 31 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedNCT02544633Phase 2Results posted
• Trial Using Gilotrif for Advanced Penile Squamous Cell CarcinomaTerminatedNCT02541903Phase 2Results posted
• A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT02537613Phase 1Results posted
• Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2Results posted
• SLM + Axitinib for Clear Cell RCCCompletedNCT02535533Phase 1/2Results posted
• Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedNCT02535338Phase 1/2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaCompletedNCT02530476Phase 1/2Results posted
• Phase I, Study in Chinese NSCLC PatientsCompletedNCT02529995Phase 1Results posted
• Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver FunctionCompletedNCT02521376Phase 1Results posted
• Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
• Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2Results posted
• Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderCompletedNCT02514174Phase 4Results posted
• A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLLActive, not recruitingNCT02514083Phase 2Results posted
• Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung AdenocarcinomaTerminatedNCT02513667Phase 2Results posted
• AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerCompletedNCT02513563Phase 2Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Active, not recruitingNCT02511106Phase 3Results posted
• (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsCompletedNCT02508532Phase 1Results posted
• A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02507375Phase 1Results posted
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation PneumonitisCompletedNCT02496585Phase 2Results posted
• A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02495233Phase 1/2Results posted
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedNCT02495103Phase 1/2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291CompletedNCT02491944Phase 1Results posted
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedNCT02488408Phase 1/2Results posted
• Trial of Ponatinib in Patients With Bevacizumab-Refractory GlioblastomaCompletedNCT02478164Phase 2Results posted
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT02477696Phase 3Results posted
• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLActive, not recruitingNCT02475681Phase 3Results posted
• Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected AdultsCompletedNCT02475655Phase 2Results posted
• Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCCompletedNCT02474355Phase 3Results posted
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02469415Phase 2Results posted
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
• Regorafenib in Metastatic Colorectal CancerCompletedNCT02466009Phase 2Results posted
• Ceritinib Rare Indications Study in ALK+ TumorsTerminatedNCT02465528Phase 2Results posted
• Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)CompletedNCT02459119Phase 2Results posted
• Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesTerminatedNCT02457598Phase 1Results posted
• Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell MalignanciesCompletedNCT02457559Phase 1Results posted
• Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursCompletedNCT02454933Phase 3Results posted
• Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT02454478Phase 1Results posted
• Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyTerminatedNCT02452463Phase 2Results posted
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsTerminatedNCT02452424Phase 1/2Results posted
• LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
• Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsCompletedNCT02450591Not applicableResults posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT02446236Phase 1Results posted
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT02443077Phase 3Results posted
• Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificCompletedNCT02442349Phase 2Results posted
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
• Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)CompletedNCT02436668Phase 3Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaCompletedNCT02432274Phase 1/2Results posted
• Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic CholangiocarcinomaCompletedNCT02428855Phase 2Results posted
• Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT02427451Phase 1/2Results posted
• A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerCompletedNCT02424617Phase 1/2Results posted
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCompletedNCT02421939Phase 3Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Ibrutinib in Treating Patients With Advanced Systemic MastocytosisTerminatedNCT02415608Phase 2Results posted
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
• Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)TerminatedNCT02410551Phase 2Results posted
• Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02404220Phase 1/2Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results posted
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedNCT02402062Phase 2Results posted
• A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal CancerTerminatedNCT02402036Phase 2Results posted
• CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedNCT02401815Phase 1/2Results posted
• An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideCompletedNCT02400476Phase 2Results posted
• A Pilot Study of Ruxolitinib in Secondary Hemophagocytic SyndromeCompletedNCT02400463Phase 2Results posted
• Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia PatientsCompletedNCT02400255Phase 2Results posted
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02399215Phase 2Results posted
• Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02393755Phase 1/2Results posted
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedNCT02393248Phase 1/2Results posted
• Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)TerminatedNCT02389764Phase 2Results posted
• ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background MethotrexateCompletedNCT02387762Phase 2Results posted
• Regorafenib Plus Gemcitabine in Metastatic Pancreatic CancerTerminatedNCT02383433Phase 2Results posted
• A Rollover Protocol of Dacomitinib For Patients In JapanCompletedNCT02382796Phase 2Results posted
• Trial of Afatinib in Pediatric TumoursCompletedNCT02372006Phase 1/2Results posted
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedNCT02371369Phase 3Results posted
• Afatinib in NSCLC With HER2 MutationCompletedNCT02369484Phase 2Results posted
• Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02368886Phase 2Results posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyCompletedNCT02365649Phase 2Results posted
• An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerActive, not recruitingNCT02365597Phase 2Results posted
• ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic CancerCompletedNCT02362048Phase 2Results posted
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
• Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone SarcomasCompletedNCT02357810Phase 2Results posted
• LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular DegenerationCompletedNCT02355028Phase 2Results posted
• Stem Cell Monitoring for CML Patients Undergoing Nilotinib TherapyCompletedNCT02353728Phase 2Results posted
• Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaTerminatedNCT02351037Phase 2Results posted
• Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)TerminatedNCT02349633Phase 1/2Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)TerminatedNCT02343939Phase 1/2Results posted
• Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid MalignanciesCompletedNCT02343120Phase 1/2Results posted
• Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid TumoursCompletedNCT02341456Phase 1Results posted
• A Study to Measure Baricitinib (LY3009104) Absorption in Healthy ParticipantsCompletedNCT02340104Phase 1Results posted
• Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesCompletedNCT02336451Phase 2Results posted

← Tyrosine Kinase Inhibitors overview